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Abstract 
Advances in healthcare technology for continence have historically been limited 
compared to other areas of medicine, reflecting the complexities of the condition and 
social stigma which act as a barrier to participation. This whitepaper has been developed 
to inspire and direct the engineering science community towards research opportunities 
that exist for continence technologies that address unmet needs in diagnosis, treatment 
and long-term management. Our aim is to pinpoint key challenges and highlight related 
research opportunities for novel technological advances. To do so, we draw on 
experience and expertise from academics, clinicians, patients and patient groups linked to 
continence healthcare. This is presented in four areas of consideration: the clinical 
pathway, patient perspective, research challenges and effective innovation. In each we 
introduce seminal research, background information and demonstrative case-studies, 
before discussing their relevance to engineering science researchers who are interested in 
approaching this overlooked but vital area of healthcare. 
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Introduction 
Incontinence is a highly prominent world-wide healthcare challenge, having a major 
impact on quality of life for millions of people, demanding increasing levels of resource 
from healthcare systems and resulting in profound socio-economic consequences. 
Incontinence does not represent a disease, rather a symptomatic condition with a complex 
and varied etiology.  It can be summarised by an inability to control the passage of faeces 
through the anus (faecal incontinence - FI) or the involuntary leakage of urine (urinary 
incontinence - UI). Longstanding social stigma means that incontinence is frequently 
under-reported however best estimates suggest that between 3-15% of community 
dwelling adults experience FI (1) while for UI this increases to 24% (men) and 53% 
(women) (2,3), the latter figure highlighting strong causative links between incontinence 
and childbirth. While the prevalence of incontinence increases with age (1), this condition 
is not limited to the elderly and a significant proportion  (0.8–7.8%) of children and 
young adults are also affected (4).  
 
Many clinical challenges persist in the management and treatment of FI and UI. Applied 
research from the engineering sciences has significant potential to directly address these 
challenges and thus improve healthcare provision and quality of life. Unfortunately, 
despite the potential health and economic gains, there has been a paucity of technological 
innovation compared with major advances in other areas of healthcare for conditions of 
similar prevalence. This might reflect the social stigma often associated with 
incontinence, which not only affects patients, but can also act as a deterrent to 
engagement by researchers in clinical, industry and academic settings. However, it is 
increasingly recognised that there is a need to accelerate innovation and that this can be 
driven by research (5). Importantly, this is not limited to the development of new 
technology, but extends to exploring ways to improve existing systems.  
 
Figure 1 illustrates the key technologies and associated research linked to continence 
technologies. A steady and significant rise in research output is evident over the last 30 
years. While this trend may be exaggerated by a more general increase in publication 
opportunity, it demonstrates that innovation is active within this clinical area and reflects 
market demands linked to an aging population (6). However, the challenge remains to 
ensure that this research is translated into sustainable outputs that will deliver real-world 
patient benefit. This is exemplified by the absorbent pads/pants used to manage fluid 
discharge which historically were home-made re-usable cotton pads until fluff was 
introduced in the nineteenth century to improve absorbency. Commercially available 
disposable products appeared in the 1920s and were in widespread use by the 1940s (7). 
From 1980 the absorbent pad market was revolutionised with the introduction of super-
absorbent polymers which could safely hold far higher volumes of fluid thus dramatically 
improving the performance of products (8). 
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Figure 1. A timeline showing the introduction of key continence technologies and 
research activity in the area. (Source: Scopus) 
 
This whitepaper has been developed to inspire and direct engineering-based research 
towards continence technologies, addressing improvements in diagnosis, treatment and 
management. Our aim is to highlight key clinical challenges, and patient needs, that 
incontinence brings and to share related opportunities for novel engineering science to 
address these areas. To do so, we draw on research, communication and case-studies 
from academics, clinicians, patients, incontinence charities, industry partners and funding 
bodies. The paper is organised into four sections; The Clinical Context presents key 
clinical aspects of healthcare for continence and significant co-morbidities, The Patient 
Perspective describes the associated needs of people who live with incontinence and 
thereafter Research Challenges identifies key technological challenges and opportunities 
that must be addressed to transform continence health care. Finally, Effective Innovation 
guides researchers on responsible practices to develop and translate research in this 
socially sensitive and clinically critical area. 
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The Clinical Context 
Incontinence is the lack of controlled release of urine or faeces. The root cause of these 
events can often be multifactorial and complex to determine. Waste products are stored in 
the body prior to emptying, urine in the bladder and faeces in the rectum. In order to 
evacuate these compartments the waste material is passed through controlled openings 
called sphincters. Sphincters are muscles controlled by either somatic or autonomic 
nerves (voluntary or involuntary) and are opened in a healthy evacuation when sufficient 
pressure in the storage compartment leads to the sensation of ‘urge’.  A failure or 
reduction in the effectiveness of these processes can lead to varying severities of 
incontinence (9). Failures can be grouped into structural issues with the sphincters or 
supporting musculature (e.g. obstetric tearing or surgical trauma), damage to the nerves 
(e.g. neuropathy and surgical trauma) and cognitive issues (e.g. dementia).  
Incontinence Healthcare 
Clinical intervention for incontinence is a complex process involving a large number of 
possible ‘pathways’ and different healthcare professionals, a reflection that this is a 
symptomatic condition with a wide array of co-morbidities and causative factors (10). In 
broad terms, the role of healthcare professionals, and related technological needs, can be 
categorised into those of assessment, intervention and management, and training. 
 
Assessment 
Assessment is essential to allow correct identification and diagnosis of conditions and 
subsequently to inform management and intervention. Assessment methods are often 
intrusive and traumatic for the person involved. Typical features of assessment are 
unnatural positioning and social discomfort for the patient, which may compromise the 
validity of test results. Assessments can be subjective, requiring skilled interpretation to 
interpret images or readings in relation to the patient’s history and presentation (Figure 
2). Furthermore, it remains challenging to combine outcomes from different modes of 
assessment to get a comprehensive evaluation of an individual’s condition and function 
(11,12). For example FI may be dependent on a number of physiological mechanisms so 
investigation requires linking evacuation defaecography which highlights pelvic floor 
dynamics and structural alterations, with manometry which measures pressure in the 
anorectum to assess the muscular contraction and relaxation of the anal sphincters (13). 
  
CONTINENCE TECHNOLOGIES WHITEPAPER: INFORMING NEW ENGINEERING SCIENCE RESEARCH 
 
 
 
Figure 2. Outputs from key clinical tools used to assess and diagnose FI a) high 
resolution anorectal manometry shows the pressure distribution along the anal canal (14) 
b) evacuation defaecography shows movement of anatomical structures and anorectal 
angle change during defecation, helping to highlight abnormalities (15) and c) endoanal 
ultrasonography provides cross-sectional views of the anal canal enabling identification 
of muscle and soft tissue defects (16). 
 
Intervention and management 
Following assessment, treatment options vary depending on physical health, age, 
mobility, and the presence of confounding factors. In general NICE guidance for UI and 
FI recommends starting with conservative approaches before committing to more 
invasive options, as shown in Figure 3 (17–19). The aim is to achieve the best functional 
outcome for the patient while minimising potentially unnecessary risk or trauma such as 
surgery under general anaesthetic. Time is typically not a critical factor in terms of the 
condition changing and this gives opportunity to explore more conservative interventions. 
Predicting which treatment strategies will be effective and for how long is often difficult 
so the exploration of intervention and management options is crucial but it can be a long 
and frustrating process for the patient.  
 
Management and treatment of incontinence are often treated as different topics but in 
reality they lie at different ends of the same intervention ‘spectrum’. Management is 
generally used to describe long-term activity to promote continence by performing a 
regular action (20) and for some, where surgical treatment is not an option, it will become 
a life-long commitment. Common management includes daily use of continence pads, 
self-catheterisation or transanal irrigation to minimise the functional impact of 
incontinence (17,21). 
In cases where the opportunity for surgical intervention exists, choice in this area is 
limited. Options include repair of damaged sphincter tissue, use of mesh and tape to 
support the pelvic floor and associated structures, sacral nerve stimulation and 
implantation of ‘neosphincters’ to augment function of the biological sphincters (22–25). 
 
CONTINENCE TECHNOLOGIES WHITEPAPER: INFORMING NEW ENGINEERING SCIENCE RESEARCH 
 
Figure 3. A summary of NICE Guidance on the treatment pathway for faecal 
incontinence in adults (19). 
Multi-Morbidity 
By 2050 the global population of older persons is projected to be more than double its 
size from that at 2015, reaching nearly 9.8 billion. As a combined result of both 
demographic and epidemiological changes, many people are now living with more than 
one long term disease as well as the symptoms and consequences of specific conditions - 
a complex scenario broadly referred to as multi-morbidity.  Multi morbidity can affect 
people across the life course, but the prevalence is much higher in older age group. 65% 
of people aged 65-84 years and 82% of people aged at least 85 years are affected with 
those over 85 having on average over 7 or more conditions (26). 
 
Dementia draws attention to the complex challenges of addressing multi morbidity.  Over 
1 million people in the UK have dementia, and 135 million are projected to have 
dementia worldwide by 2050.  People with dementia have among the highest levels of 
multi-morbidiity of any long term disorder (27). As the population ages the prevalence of 
dementia and incontinence is increasing, as are the number of people living at home with 
both these conditions (28). Incontinence is common in people with severe dementia and 
those approaching the end of life and is a powerful predictor of admission to long term 
care facilities.  Over 50% of people living in UK care homes have dementia and 
incontinence (29).   
 
Urinary incontinence is a common symptom of Parkinson’s disease (PD), as the brain’s 
control of the sphincter is disturbed and the bladder becomes overactive and wants to 
empty even when there is just a small amount of urine present, resulting in urgency, 
frequency, incontinence and repeated night-time urination. Further research is needed on 
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devices and techniques to best manage incontinence in people with conditions like 
dementia and Parkinson’s and to develop appropriate care pathways for these 
populations.    
Clinical Pathways 
When new technologies are developed they need to fit both into patient’s life, and into 
existing clinical pathways, if they are to be successfully adopted. A new technology must 
offer benefits when compared to existing practices. This may be by improving 
diagnosis/treatment or management, or it may be equivalent to existing practice but save 
time or reduce cost. New technologies that require users to be trained or learn complex 
activities, or require significant behaviour change or upfront costs, can find adoption into 
practice difficult. 
 
Innovation in bladder diaries is an example of how technology can be designed with 
clinical pathways in mind to improve healthcare and reduce cost. An electronic bladder 
diary system has been developed with guidance from patients and GPs to provide a 
digital alternative which meets patient needs and fits with clinical practice (30). Existing 
bladder diaries are paper based, non-intuitive, and require calculations to be performed by 
the GP, and as a result the collected information may be incomplete and/or inaccurate or 
not used to full effect. By performing functions such as automating data collection, 
storage and analysis, this digital system helps reduce GP workload and enables patient 
adherence to be monitored remotely.  These systems must ensure that they are accessible 
and can accommodate different age groups, and those with visual or physical 
impairments (e.g. limited manual dexterity). Further research is required to fully 
investigate these factors. However, if successful the information collected can help 
inform treatment, which may include prescribing lifestyle changes, medication, 
requesting samples for further diagnosis, or referring the patient on for assessment by a 
specialist.  
 
 
Key points: 
 
 Current assessment methods can be invasive and often traumatic, and 
evaluation across different modes of assessment is challenging. 
 
 Management of incontinence can be a lifelong commitment and there is an 
increasing need to consider multi-morbidities. 
 
 New technologies must offer benefits over existing practices and be user 
friendly. 
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The Patient Perspective 
Considering the clinical implications alone neglects the intense psychological impact of 
incontinence (particularly FI) and its powerful effect on an individual’s wellbeing, health 
and life. This section considers key needs from a patient perspective, combining research 
literature with personal accounts from people with incontinence, illustrated in Figure 4, to 
highlight their relevance and impact on everyday life. 
Enhancing Self-Confidence 
Self-esteem is often significantly impacted by the social stigma associated with 
incontinence (29), so building a strong foundation of self-confidence is crucial. Studies 
on the prevalence of incontinence suggest that many people living with incontinence 
suffer in silence rather than looking for help (31). Key factors which influence people’s 
self-esteem are the unpredictability associated with continence, a need to feel ‘normal’ 
and having sufficient knowledge to empower decision making.  
 
Addressing the complicated, erratic and unpredictable nature of incontinence is one of the 
greatest worries for individuals who do venture out in public and creates an 
overwhelming feeling that life is out of control. In an effort to take charge of their 
condition it leads people to restrict diet, become preoccupied with access to toilet 
facilities and significantly limit what they do (32,33). To feel normal people instinctively 
want to hide their incontinence and many individuals relate the profound distress 
experienced as a result of accidents. It is critical that technology can help meet these 
demands, with a form, function and performance which causes minimum disruption and 
can be relied upon. FI episodes are consistently reported as being the most difficult and 
degrading but although many people find anal plugs useful, their performance is limited 
so that in the context of a major episode they fail. One further example is the ‘rustling’ 
noise made by stoma bags as they move whichis frequently a cause of complaint even 
though it is secondary to their main function as a containment system. Another recurring 
topic is smell and odour. Currently no products exist which give people confidence to 
believe they don’t smell even when the incontinence is contained and there is clear 
opportunity for technologies which reinvent how smell is detected and controlled (34,35). 
 
Better understanding of what causes incontinence and how it can be managed or treated 
empowers people to have the confidence to make decisions regarding the treatment 
choices available and, where appropriate, challenge what is offered to them, rather than 
‘make do’ with treatments that are not best suited for them. (36–39). Lack of, or 
inaccurate, detailed information about the treatments available for their condition can 
result in people settling for coping alone, believing that the medical help offered is not 
individually tailored to their unique case. Recent initiatives like the web-based 
“Continence Product Advisor” have started to address this by placing evidenced 
information on continence care into the public domain in an accessible form (40) but 
there is also a need for personalised advice to give people the confidence to try, and to 
persist, with the medical solutions being offered (41–45). This is particularly relevant for 
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long-term interventions like pelvic floor retraining in which improvements are likely to 
be incremental, so effective information feedback is vital to promote engagement.  
 
 
 
Patient 
Perspectives
Self-
Confidence
Social 
Activity
Inclusivity“My son has bladder and bowel incontinence. He has 
bowel accidents at least once 
a week which is extremely 
embarrassing for him. He 
sometimes does not want to 
go out if he has not gone to 
the toilet. He is also 
registered as visually impaired 
so relies on either myself or 
husband to help clean him 
up.”

Personalisation

Age & Aging
“For the majority of my 34 years I’ve kept my daily accidents a secret. Even as a 
four year old I remember hiding my dirty underwear from my parents. By the time 
I reached comprehensive school I was dealing with my accidents completely on my 
own: hand washing dirty pants in the bath at home; buying replacement 
underwear with paper round money. 
“There is not a single incontinence pad available 
for children, it is presumed they will wear 
nappies, but now my very self-aware 7 year old 
does not want to wear pull ups to school and I 
don't blame her. I have searched everywhere and 
there are only adult pads available and they are 
huge”
Interaction

Beyond 
Functional
“I am going on a long coach trip 
and already thinking of cancelling. 
I have an awful bowel problem 
that’s really unpredictable What if 
I can’t get to the toilet in time? A 
pad won’t hide the smell - maybe 
if I don’t eat for a few days before 
I go this might help”
I am a qualified doctor but currently 
unable to work due to poorly 
managed FI. As well as affecting 
education and work, urinary 
incontinence and faecal incontinence 
can impact on self-esteem and 
relationships to a huge degree, which I 
feel can be underestimated by many 
health professionals and those who 
are not `affected by these conditions.”
“At junior school I 
would have regular 
accidents and be 
taunted constantly in 
the playground for 
‘smelling like fish’. I 
didn’t have any 
friends. I always 
wanted to sit inside at 
break to avoid the 
bullies. I couldn’t be 
like other children, 
getting on with their 
school day and taking 
part in sleepovers or 
school trips.”

Normality
“During my time as a student, going to 
the toilet during breaks or lunch wasn’t a 
positive experience. The few times I went 
in there, especially in High School, made 
me want to get in quick and get out. 
Already self-conscious and low self-
esteem because of living with Encopresis 
meant that doing anything other than a 
tinkle was out of the question”

Knowledge
“It’s always a new person and they always say a 
different thing to what the other doctors said.”

Unpredictability
Carers
“Alongside faecal incontinence, I have co-existing 
chronic, severe constipation to the point of developing 
faecal impactions high up in my colon. Laxatives work 
very unpredictably and usually lead to bowel accidents, 
which are understandably very distressing.”
“As part of a bowel 
transplant operation I had 
an ileostomy. I had spent 
the best part of thirty years 
on various medical bags but 
with a stoma you lose 
control of the very thing 
you take for granted, going 
to the toilet. The nerve 
endings are cut and you 
have no idea how much 
comes out or when.“

Physical
Capability
“I am desperate to reach a point where I 
am in control of my bowel, and it is not in 
control of me. I want to get back to work 
and use my own experiences to positively 
impact my patients’ lives.”
“I just felt it was wholly inappropriate for 
me to be helping my mother in law – who 
was such a dignified woman all her life -
clear up after she was incontinent.  Even 
though she had advanced dementia, she 
was very distressed by this…”
“We could do nothing when it became bad. 
We just became prisoners in the four walls. 
Just about any journey was too much…we 
packed in seeing everybody
“it was not the dementia, per se, that 
broke us.  It was him being doubly 
incontinent.  There was no real support, 
not really.  And it was so unpredictable.  
We had carers coming in but it could 
happen five minutes after they left and 
three or four times again before they 
came back on the night.  We just 
despaired”
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Figure 4. The Patient Perspective: personal experiences relayed by users of continence 
technology. Sources: IMPRESS Network1, NIHR Devices for Dignity2, ERIC UK3, 
BBUK4, VOICE North5. 
Supporting Social Activities 
Active participation in social activity is key to maintaining good quality of life. These 
activities enable people to maintain, rather than shy away from, social contact and to 
pursue life-enhancing experiences. The challenges posed by incontinence in this area can 
be difficult to assess but their importance should not be overlooked (46). 
 
Social interaction is a common challenge for those affected. There is a need for security 
in daily social contact to help individuals interact fully in school, at work and through 
leisure pursuits rather than avoiding these activities, and the associated social interaction, 
due to their condition (47). Equally, the emotional and physical consequences of 
incontinence can disrupt sexual function and/or behavior, placing strain on intimate 
relationships (48,49). 
 
Technology should not stop at allowing people to ‘get by’ with their condition, but 
should also aspire to facilitate popular life-enhancing experiences such as sport and 
travel. It needs to empower individuals to pursue the hobbies they enjoy, unrepressed by 
their condition and without fear of embarrassing incidents (50,51). 
Raising Inclusivity 
The diversity of people affected by incontinence creates a variety of individual needs but 
continence technologies have traditionally been designed to serve a far more limited 
population. Adopting inclusive, adaptable design practices would help to bring benefit to 
a far broader range of those affected by incontinence. 
 
Age, and aging are factors with particular resonance for incontinence because the 
physiological mechanisms associated with continence change as part of the natural 
ageing process. There is a consequent need for technology which can help improve 
quality of life for people of all ages across the life course. A key issue for users of every 
day management products such as pads is the need for a new direction towards a product 
that can adapt, or be adapted, to personal size and shape. The options available to people 
could be improved by introducing a comprehensive range of age appropriate or age 
adaptive solutions. Personalisation must include often overlooked users such as children 
beyond toilet training age for whom there is a huge deficit in provision, or dementia 
sufferers requiring products which can adapt to diminishing mental function (52–55). 
 
                                                 
1 www.impress-network.com  
2 www.devicesfordignity.org.uk 
3 https://www.eric.org.uk/ 
4 www.bladderandboweluk.co.uk/ 
5 www.voicenorth.org/ 
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There is also much scope to improve the provision for people with physical impairment 
which often co-exist with incontinence such as age related arthritis and visual 
impairment, spinal injury or Multiple Sclerosis. Technology has the capability to break 
down barriers to self-management that currently exist for people with a physical 
impairment, enabling people to perform daily toileting routines autonomously and 
thereby maintain independence.(56,57). 
 
Caring for someone living with long term conditions can be challenging, with continence 
problems having the greatest impact.  New designs need to be mindful of the profound 
effect incontinence has on carers and those living with people affected by it (58). The 
experience is often stressful, physically demanding and can inhibit employment (55). In 
many cases carers and family members could often benefit from greater inclusion, 
training in areas such as changing catheters and washing the person safely, and 
involvement in decision making (59).  
 
Key Points: 
 
 New technology must address the need for normality and personal 
confidence – mininising lifestyle and ensuring reliable ‘failsafe’ performance 
 
 Smell is unchartered. There is opportunity to address how smell is detected 
and/or controlled. 
 
 There is a real need for personalisation inclusivity in design for all ages, those 
with physical and mental impairment and multi-morbidities 
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The Research Challenge 
For continence technologies, the research challenge encompasses a wide range of 
underpinning knowledge and technology. Here we highlight and discuss key engineering 
and physical science challenges which include both the development of new 
understanding and technology, and the translation of extant technology to this often 
overlooked field (60). Addressing these challenges has the potential to bring forth 
disruptive changes or to bring incremental improvements in overlooked areas. In turn this 
will help bring short and long-term benefits to the diagnosis, treatment and management 
of continence to profoundly improve the lives of sufferers. 
 
Figure 5. A summary of key research fields of relevance to continence healthcare and 
associated opportunities for technological advances  
Basic Science  
Interdisciplinary basic science research, combining materials science, mechanical and 
chemical engineering with biology, including biochemistry, cell biology, molecular 
biology and neuromuscular physiology, is essential in achieving better continence 
healthcare.  
 
Improved understanding of the pathophysiology underlying the onset of incontinence is 
essential, firstly to bring clarity to what can be considered part of the 'normal' ageing 
process and secondly to understand the impact of ageing on progression of the condition 
(61). In addition, research needs to take into account the differences in anatomy between 
the sexes, in particular to better define the changes which occur with pregnancy, 
childbirth and during the postpartum period (62). These advances have the potential to 
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inform preventative measures, by identifying 'at-risk' populations and intervening 
appropriately, as exemplified by efforts to use stem-cell injections as a therapeutic 
intervention immediately after childbirth to accelerate the healing process (63).  
 
The use of new imaging techniques combined with basic science will be instrumental in 
improving assessment of incontinence by providing a better picture of how the complex 
physiological mechanisms operate and are effected over time. For example, near infra-red 
spectroscopy (NIRS) can reveal the hemodynamics of musculature while open MRI can 
reveal its 3D structure, thereby helping to quantify the functional performance of the 
pelvic floor (64). In tandem, it is important to note how new imaging techniques can act 
to reduce the invasiveness of clinical assessment and diagnosis which is currently cited as 
an invasive and unpleasant experience (often leading to poor compliance). 
 
Research exploring the neuromuscular action of the bladder and bowel has transformed 
our understanding of how these structures are actively controlled, featuring complex 
feedback systems which respond to a range of physical stimuli (65). However, more 
research is required to advance neuromuscular science and inform technologies such as 
neuromodulation which has brought life-changing improvement in continence for many 
patients despite a lack of understanding on its specific functional mechanisms. This will 
also enable clinicians to better identify patients in which these interventions are likely to 
be successful, avoiding unnecessary and costly trial evaluations (24). 
Materials and Coatings 
The advent of new materials and coatings has produced incremental benefits for 
continence. Notable examples include the emergence of disposable stoma bags and more 
recently pants and pads with super-absorbent properties. A variety materials are now 
available that directly interact with tissues in the body to provide support, deliver active 
ingredients, or provide guidance of new tissue growth. This includes synthetic materials 
and biologically-derived materials that may be permanent implants or dissolve over time. 
Synthetic polymers (e.g. polypropylene, polyethylene, PET, ePTFE have been widely 
used for pads, catheters, surgical meshes, and stoma bags (66–68). Materials have been 
used to augment anatomical structures, for example polyacrylamide hydrogels used as a 
bulking agent to treat urinary incontinence in women (69)). Other materials can support 
cell attachment, proliferation, and differentiation. Flexibility in the manufacture and 
processing of these materials allows for the ability to tailor their chemistry and rates of 
biodegradation (70). The application of materials science is not restricted only to 
polymers. Metals have also been used in devices for load bearing applications. For 
example, artificial sphincters which utilise titanium and iron-based materials for 
structural and actuation functionality (71). Although over the years significant progress 
has been made in the design of novel material formulations, multiple challenges remain. 
Among these, the most critical are acute and chronic foreign body responses, the risk of 
infection, and the presence of inappropriate mechanical properties. 
 
Over the past decade efforts have been made to optimise catheter surfaces in an attempt 
to reduce the occurrence of urinary tract infection and encrustation (72,73). Organic and 
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inorganic materials have been mooted as potential methods of reducing bio-film 
formation and increasing lubricity. Hydrogel coatings (i.e. networks of crosslinked 
polymer chains in an aqueous solvent) are available and effective in reducing bio-film 
formation, trauma and encrustation due to their hydrophilic nature (74,75). However pain 
during insertion, erosion of mucosal and uro-epithelial layers, encrustation and infection 
is still common with catheters. There is opportunity to continue advancing this field; a 
wide range of polymer-based systems exist commercially, whilst many more are being 
actively developed by researchers. These range from simple hydrogel coatings to 
complex gel chemistries containing active and passive antibacterial and antifouling 
additives. Without doubt, a functional catheter-biology interface is key if successful 
intermittent and indwelling catheterisation is to be achieved. 
Fabrication  
In developing new technology it is beneficial to work with a range of specialists that have 
the ability to address different aspects of the product design-cycle as early as possible. 
Valuable contributors might include clinical engineering departments within hospitals, 
departments within universities such as engineering, chemistry, design or computing, 
design consultancies, and potential future licensees for the technology under 
development. Rapid prototyping has made the product design and development process 
more accessible to individuals with new ideas they would like to test (76). Careful 
product design can make the difference between a new item of technology being 
accepted, tolerated or rejected by end users. For instance, users of continence products 
continue to seek alternatives to bulky and non-washable, non-flushable continence pads. 
A well-managed product design process encompasses user interfaces, production 
methods and capabilities, planning for potential medical technology regulations, and may 
involve many iterations. These aspects are all in addition to the underlying function of the 
technology and may help the technology to meet usability engineering requirements for 
regulatory compliance. 
 
Further difficulties can arise when trying to upscale production of tested technologies into 
medium or large scale, as these cannot usually be produced within hospital or university 
facilities. Additionally, high cost-per-item sums may be appropriate when costed into a 
research proposal, but cannot usually be carried through to scaled-up production. It is 
therefore instructive to seek manufacturing expertise early in the development cycle, as 
manufacturers will be able to advise on potential costs-saving production methods, and 
can provide crucial advice on what is (or is not) feasible at scale. 
Smart Systems 
Smart systems describe the application of sensing and/or actuation technology to 
transform previously ‘passive’ devices into ‘active’ systems with the capacity to monitor 
and react to the environment. Key challenges of applying such technology to 
incontinence are the challenging working environment (including contact with human 
tissue, reactive fluids and movement), delivering cost-effective solutions (e.g. is it 
feasible to instrument a disposable/single-use product) and biocompatibility/bio-
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integration (e.g. to avoid aggravation of sensitive tissues). However, research advances in 
fields including materials, electronics and communications can help overcome these 
challenges to bring innovative new technology for assessment, treatment and long-term 
management of incontinence. For example, researchers have developed a ‘smart diaper’ 
by embedding a moisture sensing Radio-Frequency Identification Tag (RFID) tag into the 
absorbent pad so that its absorbent capacity can be determined (77,78). The combination 
of technology is important since RFID provides a low cost solution (suited for disposable 
pants) in a biocompatible form which can be monitored wirelessly and remotely (e.g. via 
a smart phone) without obtrusive connective wires. This has particular relevance in care 
home settings, making it both quicker and more efficient for nursing staff to monitor their 
patients and ensure they receive optimum care. Another form of sensing with the 
potential to be transformative is a wearable odour sensing system with the ability to 
detect, with high sensitivity, the presence of smells associated with incontinence (79). 
Using a similar approach to smart pants/pads, real-time feedback is provided wirelessly 
to a smartphone device, in this case informing the wearer about relevant odour levels. 
This illustrates the capacity of technology to address common personal anxieties 
associated with incontinence such as ‘smell’ and ‘normality’. There is opportunity for 
further innovation in the combined use of different sensing modalities and implantable 
sensors for long-term monitoring (80). This is highlighted by early research into 
implantable sensors to monitor attributes of the bladder like pressure, volume and 
contraction (81–83). The use of actuators is less developed but recent research highlights 
their promise to address and transform areas where no solution exists, particularly in 
faecal incontinence. Key examples include a smart biomimetic sphincter using electro-
active-polymers (EAPs) (84) and a novel artificial sphincter using active pressure control 
to prevent tissue erosion (85).  
Informatics 
Informatics is a growing field in healthcare, used to explore how clinical interventions 
affect the patient perspectives of self-confidence, social activities, inclusivity; as well as 
its impact on clinical practice. Its growth has been catalysed by advances in digital and 
cloud technologies, notably the ubiquity of mobile devices which can be used for data 
gathering, storage and analysis of healthcare data, often termed ‘MHealth’ (86).  
 
There has been limited application of informatic and MHealth technology to address 
healthcare for continence, yet this represents an area in which huge gains could be made 
for patient benefit. A mobile app developed to guide self-treatment of stress urinary 
incontinence (e.g. through pelvic floor exercise regimes, dietary and lifestyle advice) has 
demonstrated the ability to bring clinical relevant improvements and furthermore bring 
cost benefits to healthcare providers (87,88). Other research demonstrates that these 
technologies can be scaled to provide comprehensive healthcare support which is tailored 
to different populations through specialised apps (e.g. to support self-catheterisation and 
bowel management) together with facilities for interaction with clinicians and monitoring 
adherence to self-care regimens (89). 
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The main challenge for informatics is developing robust evidence. This is currently 
hindered by the lack of published studies as there is a relatively small population to 
sample from combined with the difficulty of breaking through the intimate nature and 
social taboos associated with continence.  For example, current studies use a variety of 
data collection methods from case notes to Skype or other online calls.  Whilst this may 
provide researchers with effective data collection tools, it is difficult to standardise the 
results/outcomes from such research, and the method has the potential to introduce bias 
when interpreting results. Advances in informatics need to consider the impact of having 
clear measurements of success and/or clinical outcomes.  Patients need to be able to 
provide their clinicians with critical information that will enhance their self-confidence, 
and clinicians need to be able to interpret this information using tools and resources to 
standardise the quality of information coming through (90). 
BioEngineering 
Biomedical engineering, encompassing tissue engineering and regenerative medicine, 
hold significant promise for the treatment of incontinence. Applications of this 
technology are already undergoing clinical testing for incontinence and a plethora of 
other approaches within this field are on the horizon. 
 
Cell therapy of sphincter tissue offers an exciting opportunity to repair and recover 
function. Studies using autologous cells, such as myoblasts (muscle precursor cells), 
explanted from other sites and transplanted into sphincter muscle, have demonstrated this 
is technically feasible and safe (91,92). This application of cell therapy has been studied 
extensively for UI, with evidence of new, functional muscle following cell delivery (93). 
Challenges remain in harvesting appropriate cells and delivering them to the target site, 
an area which remains a focus of current research  (94,95).  
An alternative approach to cell therapy is the use of three-dimensional bioengineered 
muscle constructs. These are being developed as replacements for damaged or 
degenerated sphincter muscle. The constructs exhibit physiological functionality and also 
provide a useful tool for studying complex physiological mechanisms underlying 
sphincter malfunction (96,97). Pre-clinical research has demonstrated the feasibility of 
surgically implanting the bioengineered construct into rodent and rabbit models of FI 
(98–101). However, the practicality of scaling-up bioengineered constructs to a size 
applicable to humans (102), complete with innervation, vascularization and cell viability, 
remains untested. Before translating to humans, new approaches for retaining the 
mechanical properties and function of the sphincter complex will be needed, along with 
robust and stable large animal models of incontinence for testing the efficacy of the 
bioengineered constructs. 
 
In addition to replacing dysfunctional sphincter muscle, it might also be possible to 
condition injured or degenerated muscle to improve continence. Cells convert mechanical 
stimuli into intracellular biomolecular signaling via mechanotransduction. Healthy 
muscle undergoes hypertrophy in response to mechanical loading and stretching. Muscle 
found in the sphincters that control bladder and bowel function are likely to respond in a 
similar manner if given an appropriate stimulus. Innovative engineering-based 
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technology capable of delivering mechanical strain to these muscles could provide the 
environmental cues necessary for stimulating therapeutic benefits. One approach 
envisaged might be the use of magnetic actuation to deliver mechanical strain, similar to 
that described for other cell types (103). Non-invasive technologies, such as actuation at a 
distance using magnetic force, to recondition sphincter muscle would be particularly 
beneficial, especially if it could provide new treatments and assistive technologies for 
rehabilitation at home. 
 
Key Points: 
 
 Advances in basic science are required to inform existing and new healthcare 
interventions (from cell therapy and tissue engineering to neuro-stimulation)  
 
 New materials, fabrication and manufacturing approaches can be applied to 
improve product performance, choice and achieving environmentally 
friendly products (e.g. biodegradable pads). 
 
 Through user-centred design, extant technology and engineering science 
could be translated to great impact (e.g. adapting smart systems and 
informatics technology used in diabetes care to inform continence 
management). 
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Effective Innovation  
Developing continence technologies is inherently an applied and multidisciplinary area. 
The concept of ‘translating’ research from ‘bench to bedside’ is now well recognised and 
has received particular attention in the pharmaceutical industry, where numerous models 
have been developed to guide the process of translation and commercialisation toward 
clinical benefit (104). The process is less well defined for non-pharmaceutical technology 
and involves different mechanisms, procedures and regulatory requirements. However, 
common themes are apparent, in particular the need to combine basic and applied 
science, have close involvement of end-users (or ‘stake-holders’) and to have a well-
defined (and funded) route from early-stage lab research toward commercial product and 
clinical utility (105). This section considers some of the key factors involved in the 
technology translation process, highlighting that it is not sufficient to have good 
technology alone to bring about patient benefit. 
 
Industry Engagement 
Industry engagement is vital to research as it enables the transfer of knowledge from the 
academic and clinical communities into commercial applications/products.  In order to 
maximise the returns on industry engagement, it is important to find the right industry 
partner. This involves identifying an opportunity or problem that industry could address 
if it had access to the knowledge from academic and clinical communities.  In general, 
universities tend to be best placed at providing access to researchers and the coordination 
of agreements, IP and delivery conditions, with the NHS having access to clinicians, 
clinical engineers, device regulatory expertise, and patient network (these functions are 
coordinated through the NIHR Office for Clinical Research Infrastructure).  This helps 
partners to build trust in the collaboration which will contribute to adapting the 
knowledge to fit the specific needs of the business processes and markets. 
 
Regulation and Approval  
In the UK, regulation of medical products is overseen by the MHRA (Medicines and 
Healthcare products Regulatory Agency6) who grant medicinal licenses to manufacturers 
and monitor the CE marking process for medical devices. The complexity in navigating 
the regulatory framework to bring a product to market is dependent on the type of 
product and the risk classification. In general, if the intended function of the product is 
not achieved through pharmaceutical means, but by physical intervention, then the 
product is classified as a medical device and is regulated by EU directives and 
regulations. The risk classification depends on a range of factors and is important to 
determine as higher risk products require greater premarket evidence for approval to be 
granted. For the highest risk category a clinical trial is mandatory. The European 
Commission provides detailed guidance (MEDDEVs7) on all aspects of the medical 
device regulatory process.  
The importance of understanding the regulatory process is underlined by the surgical 
mesh kits introduced to provide pelvic floor support. Commercial drivers saw the product 
                                                 
6 www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency 
7 http://ec.europa.eu/growth/sectors/medical-devices/guidance_en 
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pushed through clinical evaluation and it received less stringent regulatory scrutiny than 
it should, eventually receiving FDA approval and widespread use throughout the USA. 
Unfortunately, the product had significant flaws, resulting in high rates of erosion, 
infection and failure; devastating for those people involved and with wider impact on this 
area of healthcare as a whole (106). 
 
User Engagement and Public Awareness 
Many people living with UI and/or FI are reluctant to talk about their condition in public. 
Therefore engaging them to be directly involved in developing new technology might 
require a different approach to conventional modes of research. Patient and public 
involvement in research is increasingly expected, if not required, by research funding 
bodies and provides the valuable but often overlooked patient perspective of new 
technology. An example of this is a questionnaire survey, conducted to gain opinion 
regarding a biomedical engineering approach to prevent or treat post-obstetric 
incontinence (107). It is therefore imperative that research encompasses the perspective 
of the end user (both patients and healthcare professionals) so that new technology 
addresses real needs or shortfalls in provision, and that it's mode of operation is 
acceptable to users and can integrate into effective clinical practice. 
 
Patient-representing charities can be a valuable source of patient input and patient 
volunteers, and charities, are increasingly working together around clinical issues to 
create force for change. In 2016 ten charities and health organisations, and the priority 
setting organisation James Lind Alliance, formed a Priority Setting Partnership (PSP). 
The group met with patients, carers, researchers, and healthcare professionals to discuss 
and explore continence; the output of this PSP includes a series of needs and 
recommendations for addressing incontinence research and development of solutions. 
Recommendations include a need to address the lack of health economic evidence for 
incontinence interventions, the awareness of researchers of the need to include patients 
and carers in the development of interventions that affect them, and improving access to 
training and education for patients and carers to self-manage and share expertise. 
 
Due to the high level of stigma associated with incontinence there is a particular need to 
be sensitive to upholding the level of privacy and confidentiality required by each 
individual participant. This may vary widely from person to person and research 
methodology should be designed appropriately in this respect. As for all research 
involving patient involvement, projects should be amenable to the needs of patients. Best 
practice for public and patient involvement is constantly evolving, and groups such as 
NIHR INVOLVE can be approached for guidance. 
 
Socio-Economic 
Many people still see incontinence as an inevitable part of ageing, which, combined with 
the taboo around it, means they don’t engage with health services or feel comfortable 
pushing for the most appropriate treatments if their treatment isn’t adequate.  
 
It is crucial that Health Economic factors are considered when developing technology for 
incontinence. In today’s society, healthcare systems are increasingly resource limited and 
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those with incontinence may need to financially support their own care if products are not 
available through the NHS. Accordingly it is important that technology is developed to be 
cost effective and appropriate to as large an audience as possible. 
 
IP management:  
Intellectual Property (IP) is the concept which enables the ownership of ideas and 
concepts which have practical applications and commercial potential.  It is important to 
secure the services of an IP specialist/expert as continence patients and carers can be a 
source of these new ideas and concepts. The identification of the actual IP is very 
important and the services of an IP specialist are key at this stage.  Once the IP has been 
identified, steps must be taken to protect it and this involves exploring the different levels 
of legal protection available.  The protection of IP is done via a set of agreements 
involving all parties that have access to these ideas and concepts.  While most are 
familiar with the concept of third party agreements, employees or those close to the 
innovation also need to understand their responsibilities and it is important that 
opportunities for IP awareness training are made available. In the UK, the Academic 
Health Science Networks, Medipex and Medilink are all organisations offering a variety 
of training and educational opportunities to support responsible innovation in this area. 
 
 
 
Key Points: 
 
 Engagement with industry at an early stage is vital for effective translation 
of research to commercial products 
 
 Patient engagement is critical but in this field requires an approach 
sensitive to individual needs for privacy. 
 
 Health Economic factors are important and should be careful considered 
alongside re-useable and disposable aspects of designs.  
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Discussion 
Current delivery of continence healthcare is skewed toward secondary and acute care 
settings, a reflection of current clinical pathways (see Figure 3) and the severity of 
conditions with which many patients present. However, this places a huge resource 
burden on the healthcare system and arguably results in a sub-optimal experience for 
many patients. In response, advisory groups and policy makers are advocating a move 
toward community-based healthcare for incontinence in which assessment, diagnosis and 
intervention can be deployed in small-clinic or home settings. Technology can, and 
should, play a key role in supporting this movement, for example driving improvements 
in less invasive and more precise assessment, providing m-Health systems to inform self-
management and advancing basic-science to support cell therapies for both prevention 
and ‘cure’.  
 
A key theme in continence healthcare is personal empowerment and inclusivity which is 
closely coupled with provision of choice. The UK market is now dominated by 
disposable versions of previously re-usable incontinence products such as pads, pants and 
catheters. While these represent technological advances (e.g. in materials) they have also 
limited personal choice. Re-usable products (e.g. bed pads, swimwear and underwear) 
remain an important part of continence management and some people, whether for 
economy or preference, still use ‘homemade’ systems such as terry toweling squares 
(either alone or in conjunction with a disposable) to manage very heavy incontinence 
(108). This highlights that availability of choice is strongly governed by the diversity of 
products manufactured by industry and that this can often be adversely affected by 
commercial factors (e.g. consolidating product/size ranges to boost economies of scale) 
and regulatory aspects (e.g. promotion of single-use medical products). 
 
A move to increased use of technology by patients and carers, particularly in non-
supervised settings, brings the potential pitfall of misuse, which may compromise the 
assessment or intervention. Therefore it is imperative to adopt user-centered design 
principles to understand, define and meet user needs and environmental constraints. The 
nature of incontinence means this is non-trivial task, since patient needs are diverse, span 
a broad age range and are often confounded by co-morbidities, as summarised in Figure 
4. However, it also presents an opportunity in which technology can be used to help 
deliver personalised interventions that can be customised to better meet patient need, for 
example ‘smart’ systems which alert the user of a need to change their pad. This links to 
common requests from patients that they wish to proactively manage their own condition, 
rather than being overly reliant on healthcare services. 
 
The personal and societal challenges associated with incontinence can often be severely 
life-limiting, impacting profoundly on activities of daily living and limiting social 
interaction. Perhaps as a consequence, the expectations for technology are often focused 
on enabling that person to cope with a minimum set of activities, for example 
maintaining continence for sufficiently long to enable them to go shopping or use public 
transport. For many people this is a valuable achievement, however others aspire to 
expand their lifestyle activities, for example taking up new sports or leisure activities, and 
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require technology which can cater to these demands. This might manifest in products 
such as stoma bags capable of supporting high levels of physical activity, or intermittent 
catheters with surface treatments enabling safe re-use to facilitate travel. Ultimately, there 
is the potential, and patient need, for technology which empowers the individual.  
 
Perhaps the key motivation of engineers and scientists working in this domain is to bring 
benefit to patients through application of their technology. It should be recognised that 
the route of translating technology ‘from bench to bedside’ is challenging and time-
consuming. Adopting an effective innovation strategy could be considered as important 
as the technology itself. Many excellent technologies fail due to aspects of 
commercialisation revealed by health-economic analysis, IP due diligence and regulatory 
investigations. Furthermore, the inherent ‘inertia’ in healthcare systems mean that 
introducing a new technology requires a compelling Cost-Benefit argument. Existing 
pathways, as illustrated in Figure 3, will not readily change unless the technology 
provides significant benefit that outweighs the difficulty and cost of changing that 
pathway. While these considerations could be viewed as a barrier to innovation, in 
actuality they are a necessary part of medical technology development and there are an 
increasing number of funding streams and organisations dedicated to supporting these 
processes. With such significant clinical challenges and compelling unmet patient needs, 
now is a critical time for scientists and engineers to apply their research expertise to 
improve healthcare for continence. 
Conclusions 
This paper has considered key factors involved in healthcare technology for continence 
care, spanning the clinical context, patient perspective, research challenges and how this 
can be implemented through effective innovation. At the heart of any research in this area 
is the need for a clear definition and understanding of what we mean by ‘incontinence’, 
how it manifests and how it interacts with other conditions. In contrast to many other 
medical conditions, these aspects are not well defined for incontinence and as such a key 
contribution is to improve our understanding of this complex, diverse and symptomatic 
condition through advances in basic sciences. Equally, many of the clinical challenges 
and research opportunities associated with incontinence could be approached through 
adoption of existing knowledge, methodology and technology being applied to other 
clinical conditions. Multidisciplinary research underpinning this activity will undoubtedly 
strengthen medical technology in this neglected area.  
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